Search

Background: Limited data exist on the characteristics of SARS-CoV-2 infections in German patients with psoriasis or psoriasis arthritis (PsA). This study analyses COVID-19 prevalence and severity of symptoms in these patients., Patients and Methods: Participants of the German registries PsoBest and CoronaBest were surveyed in February 2022. Descriptive analyses were conducted., Results: 4,818 patients were included in the analysis, mean age of 56.4 years. Positive SARS-CoV-2 tests were reported by 737 (15.3%) patients. The most frequently reported acute symptoms were fatigue (67.3%), cough (58.8%), and headache (58.3%). Longer-lasting symptoms after COVID-19 were reported by 231 of 737 patients after the acute phase. For most patients (92.9%), systemic treatment for their psoriasis or PsA was not modified during the pandemic. Patients positively tested for SARS-CoV-2 were younger on average and had more often changes in the therapy of psoriasis than negatively tested patients (8.5% vs. 5.4%)., Conclusions: In this cohort of patients with psoriasis or PsA undergoing systemic treatment, SARS-CoV-2 infections were common but less frequent than in the general German population. No risk signals for more severe COVID-19 or increased infection rates were observed in the patients. In addition, systemic treatments remained largely unchanged, so that no risks can be attributed to these therapies., (© 2024 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by Wiley‐VCH GmbH on behalf of Deutsche Dermatologische Gesellschaft.)

Background: The ventilatory mechanics of patients with COPD and obesity-hypoventilation syndrome (OHS) are changed when there is air trapping and auto-PEEP, which increase respiratory effort. P 0.1 measures the ventilatory drive and, indirectly, respiratory effort. The aim of the study was to measure P 0.1 in subjects with COPD or OHS on treatment with positive pressure and to analyze their changes in P 0.1 after treatment., Methods: With a prospective design, subjects with COPD and OHS were studied in whom positive airway pressure was applied in their treatment. P 0.1 was determined at study inclusion and after 6 months of treatment., Results: A total of 88 subjects were analyzed: 56% were males, and the mean age of 65 ± 9 y old. Fifty-four (61%) had OHS, and 34 (39%) had COPD. Fifty (56%) had air trapping, with an initial P 0.1 value of 3.0 ± 1.3 cm H 2 O compared with 2.1 ± 0.7 cm H 2 O for subjects who did not have air trapping (P = .001). After 6 months of treatment, subjects who had air trapping had similar P 0.1 as those who did not: 2.3 ± 1.1 and 2.1 ± 1 cm H 2 O, respectively (P = .53). In subjects with COPD, initial P 0.1 was 2.9 ± 1.4 cm H 2 O and at 6 months 2.2 ± 1.1 cm H 2 O (P = .02). In subjects with OHS, initial P 0.1 was 2.4 ± 1.1 cm H 2 O and at 6 months 2.2 ± 1.0 cm H 2 O (P = .28)., Conclusions: COPD and air trapping were associated with greater P 0.1 as a marker of respiratory effort. A decrease in P 0.1 indicates less respiratory effort after treatment., (Copyright © 2022 by Daedalus Enterprises.)